Increased GATA-3 and T-bet expression in eosinophilic esophagitis versus gastroesophageal reflux disease - 04/05/18
This study was funded by Mayo Clinic, Phoenix Children's Hospital Foundation, and Don and Kathy Levin Family Foundation (B.L.W., J.J.L.). This work was also supported by the Consortium of Eosinophilic Gastrointestinal Disease Researchers (grant no. U54AI117804), which is part of the Rare Disease Clinical Research Network, an initiative of the Office of Rare Disease Research, National Center for Advancing Translational Sciences (NCATS), and is funded through a collaboration between the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, NCATS, and patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED), the Campaign Urging Research for Eosinophilic Disease (CURED) and the Eosinophilic Family Coalition (EFC). The National Institutes of Health provided grants 1K24DK100303 (G.T.F.) and T32DK067009-11 (N.N.). This work benefitted from data assembled by the ImmGen consortium. |
|
Disclosure of potential conflict of interest: B. L. Wright's institution received a grant from Don and Kathy Levin Family Foundation for this work. E. A. Jacobsen's institution received a grant from the National Institutes of Health (NIH) for this work. G. T. Furuta received consultancy fees from Shire; grants from the Food and Drug Administration and the NIH for other works; and royalties from UpToDate. J. J. Lee is cofounder of EnteroTrack. |
Vol 141 - N° 5
P. 1919 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?